Who is sponsoring NCT03897842?

NCT03897842 is sponsored by CardioRenal Systems, Inc..

What drugs are being tested in NCT03897842?

Interventions in NCT03897842: Reprieve Cardiovascular System.

What condition does NCT03897842 study?

NCT03897842 studies Congestive Heart Failure.

Is NCT03897842 still recruiting?

NCT03897842 is currently status unknown. Last updated 1 April 2019.

Last reviewed 2019-04-01 · How we verify

NCT03897842

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TARGET: A Study to Evaluate the Treatment of Patients With Acute Decompensated Heart Failure (ADHF) Using an Automated Fluid Management System

Status unknown NA Last updated 1 April 2019

What this trial tests

NA trial testing Reprieve Cardiovascular System in Congestive Heart Failure in 40 participants. Status unknown.

Timeline

16 March 2017

Primary endpoint
1 December 2019

1 January 2020

Quick facts

Lead sponsor	CardioRenal Systems, Inc.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	16 March 2017
Primary completion	1 December 2019
Estimated completion	1 January 2020
Sites	1 location across Poland

Drugs / interventions tested

Reprieve Cardiovascular System

Conditions studied

Congestive Heart Failure — all drugs for Congestive Heart Failure →

Sponsor

CardioRenal Systems, Inc.

Who can join

18 and older, any sex, with Congestive Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single arm, early feasibility study designed to evaluate the safety and device performance of The RenalGuard System in the management of patients admitted with signs and symptoms of congestive heart failure who require diuresis for the treatment of volume overload.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Controlled decongestion by Reprieve therapy in acute heart failure: results of the TARGET-1 and TARGET-2 studies.
Biegus J, Zymlinski R, Siwolowski P, Testani J, et al · · 2019 · cited 31× · PMID 31127666 · DOI 10.1002/ejhf.1533
Device-based therapy for decompensated heart failure: An updated review of devices in development based on the DRI<sub>2</sub>P<sub>2</sub>S classification.
de Oliveira Cardoso C, Elgalad A, Li K, Perin EC. · · 2022 · cited 6× · PMID 36211544 · DOI 10.3389/fcvm.2022.962839
Device therapies for heart failure with reduced ejection fraction: a new era.
Mody R, Nee Sheth AB, Dash D, Mody B, et al · · 2024 · cited 5× · PMID 39494238 · DOI 10.3389/fcvm.2024.1388232
Device-based therapies in cardio-renal syndrome: a pathophysiology-driven approach to a complex bidirectional disease
Echefu G, Sullivan R, Stowe I, Ukwuani P, et al ·
Advances and controversies in acute decompensated heart failure treatment: beta-blocker roles, emerging devices, and future directions.
Milhem F, Almur O, Hajjeh O, Bdair M, et al · · 2025 · PMID 40901193 · DOI 10.1097/ms9.0000000000003592

Verify or expand the search:

Other trials of Reprieve Cardiovascular System

Trials testing the same drug.

NCT05015764 — Reprieve Cardiovascular System for the Treatment of Subjects With Acute Decompensated Heart Failure Mechanistic Study · NA · completed
NCT03866551 — Reprieve ADHF EFS IDE · NA · unknown

Other recruiting trials for Congestive Heart Failure

Currently open trials in the same condition.

NCT07008365 — The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure · Phase 3 · recruiting
NCT06526884 — Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC) · NA · active not recruiting
NCT06495892 — PVP-Guided Decongestive Therapy in HF 2 · Phase 4 · recruiting
NCT06374277 — Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence · NA · recruiting
NCT05971225 — Verifying Remote Monitoring Effect on Net Cardiovascular Outcome; RemoteVerify (RêVe) · NA · recruiting

Other CardioRenal Systems, Inc. trials

Trials by the same sponsor.

NCT07123935 — Safety & Efficacy of RenalGuard® Therapy in the Prevention of Cardiac Surgery Associated Acute Kidney Injury · NA · not yet recruiting
NCT06811805 — Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI · NA · active not recruiting
NCT03866551 — Reprieve ADHF EFS IDE · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03897842 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CardioRenal Systems, Inc.
Last refreshed: 1 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03897842.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing